Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus
M. J. Davies1, A. Trujillo1, U. Vijapurkar2, C. V. Damaraju2 & G. Meininger2
1
Janssen Scientific Affairs LLC, Raritan, NJ, USA
2
Janssen Research and Development LLC, Raritan, NJ, USA
Correspondence to: Michael J. Davies, Janssen Scientific Affairs LLC, 1000 US Highway 202, Raritan NJ, 08869, USA. E-mail: [email protected] Tel.: +1 908-927-6502 Fax: +1 908-227-4631
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dom.12439
This article is protected by copyright. All rights reserved
Abstract Hyperuricaemia is associated with increased risk of gout, kidney stones, and cardiovascular disease. This post hoc analysis of pooled data from four placebo-controlled phase 3 studies assessed the effect of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, on serum uric acid levels in patients with type 2 diabetes mellitus (T2DM) and in a subset of patients with hyperuricaemia (defined as baseline serum uric acid ≥8 mg/dl [~475 μmol/l]). At week 26, canagliflozin 100 mg and 300 mg were associated with an approximately 13% reduction in serum uric acid compared with placebo. In the subset of patients with hyperuricaemia, placebo-subtracted percent reductions in serum uric acid were similar to the overall cohort. More hyperuricaemic patients achieved a serum uric acid level of
M. J. Davies1, A. Trujillo1, U. Vijapurkar2, C. V. Damaraju2 & G. Meininger2
1
Janssen Scientific Affairs LLC, Raritan, NJ, USA
2
Janssen Research and Development LLC, Raritan, NJ, USA
Correspondence to: Michael J. Davies, Janssen Scientific Affairs LLC, 1000 US Highway 202, Raritan NJ, 08869, USA. E-mail: [email protected] Tel.: +1 908-927-6502 Fax: +1 908-227-4631
This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/dom.12439
This article is protected by copyright. All rights reserved
Abstract Hyperuricaemia is associated with increased risk of gout, kidney stones, and cardiovascular disease. This post hoc analysis of pooled data from four placebo-controlled phase 3 studies assessed the effect of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, on serum uric acid levels in patients with type 2 diabetes mellitus (T2DM) and in a subset of patients with hyperuricaemia (defined as baseline serum uric acid ≥8 mg/dl [~475 μmol/l]). At week 26, canagliflozin 100 mg and 300 mg were associated with an approximately 13% reduction in serum uric acid compared with placebo. In the subset of patients with hyperuricaemia, placebo-subtracted percent reductions in serum uric acid were similar to the overall cohort. More hyperuricaemic patients achieved a serum uric acid level of
